Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Mark A. Jacobson, Donald I. Abrams, Paul A. Volberding, Peter Bacchetti, Judith Wilber, Richard E Chaisson, Suzanne Crowe, Walter Howard, Andrew Moss

Research output: Contribution to journalArticle

Abstract

Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

Original languageEnglish (US)
Pages (from-to)1029-1036
Number of pages8
JournalJournal of Infectious Diseases
Volume159
Issue number6
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Zidovudine
Serum
HIV
Placebos
Anti-Retroviral Agents
AIDS-Related Complex
Therapeutics
Antigens
Virus Diseases
Acquired Immunodeficiency Syndrome
Biomarkers
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Jacobson, M. A., Abrams, D. I., Volberding, P. A., Bacchetti, P., Wilber, J., Chaisson, R. E., ... Moss, A. (1989). Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine. Journal of Infectious Diseases, 159(6), 1029-1036. https://doi.org/10.1093/infdis/159.6.1029

Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine. / Jacobson, Mark A.; Abrams, Donald I.; Volberding, Paul A.; Bacchetti, Peter; Wilber, Judith; Chaisson, Richard E; Crowe, Suzanne; Howard, Walter; Moss, Andrew.

In: Journal of Infectious Diseases, Vol. 159, No. 6, 1989, p. 1029-1036.

Research output: Contribution to journalArticle

Jacobson, MA, Abrams, DI, Volberding, PA, Bacchetti, P, Wilber, J, Chaisson, RE, Crowe, S, Howard, W & Moss, A 1989, 'Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine', Journal of Infectious Diseases, vol. 159, no. 6, pp. 1029-1036. https://doi.org/10.1093/infdis/159.6.1029
Jacobson, Mark A. ; Abrams, Donald I. ; Volberding, Paul A. ; Bacchetti, Peter ; Wilber, Judith ; Chaisson, Richard E ; Crowe, Suzanne ; Howard, Walter ; Moss, Andrew. / Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine. In: Journal of Infectious Diseases. 1989 ; Vol. 159, No. 6. pp. 1029-1036.
@article{d4bcb6e6ed7f42ef84a74429cb1e628c,
title = "Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine",
abstract = "Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.",
author = "Jacobson, {Mark A.} and Abrams, {Donald I.} and Volberding, {Paul A.} and Peter Bacchetti and Judith Wilber and Chaisson, {Richard E} and Suzanne Crowe and Walter Howard and Andrew Moss",
year = "1989",
doi = "10.1093/infdis/159.6.1029",
language = "English (US)",
volume = "159",
pages = "1029--1036",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

AU - Jacobson, Mark A.

AU - Abrams, Donald I.

AU - Volberding, Paul A.

AU - Bacchetti, Peter

AU - Wilber, Judith

AU - Chaisson, Richard E

AU - Crowe, Suzanne

AU - Howard, Walter

AU - Moss, Andrew

PY - 1989

Y1 - 1989

N2 - Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

AB - Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

UR - http://www.scopus.com/inward/record.url?scp=0024348488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024348488&partnerID=8YFLogxK

U2 - 10.1093/infdis/159.6.1029

DO - 10.1093/infdis/159.6.1029

M3 - Article

C2 - 2566637

AN - SCOPUS:0024348488

VL - 159

SP - 1029

EP - 1036

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -